Mike Nally, Generate:Biomedicines CEO
Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near
The AI-focused biotech Generate:Biomedicines announced another pharma partnership Tuesday, agreeing to work on several protein therapies with the Swiss drugmaking giant Novartis.
Novartis will pay …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.